- Trials with a EudraCT protocol (13)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
13 result(s) found for: Reticulocyte index.
Displaying page 1 of 1.
EudraCT Number: 2017-004889-10 | Sponsor Protocol Number: DapaFIT | Start Date*: 2021-04-28 |
Sponsor Name:University Hospital Tuebingen | ||
Full Title: Dapagliflozin effect on erythropoiesis and physical fitness in patients with type 2 diabetes - a randomized, partly double-blinded, controlled, three armed, parallel group, exploratory study | ||
Medical condition: Patients with T2DM and hypertension aged 40 to 70 years (including) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2018-004220-11 | Sponsor Protocol Number: APL2-308 | Start Date*: 2019-07-23 | |||||||||||
Sponsor Name:Apellis Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Multicenter, Open-Label, Controlled Study to Evaluate the Efficacy and Safety of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) | |||||||||||||
Medical condition: Paroxysmal Nocturnal Hemoglobinuria (PNH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004268-36 | Sponsor Protocol Number: APL2-302 | Start Date*: 2018-10-01 | |||||||||||
Sponsor Name:Apellis Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase III, Randomized, Multi-Center, Open-Label, Active-Comparator Controlled Study to Evaluate the Efficacy and Safety of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) | |||||||||||||
Medical condition: PNH is an acquired, rare, clonal, non-malignant hematologic disease characterized by complement-mediated RBC hemolysis with or without hemoglobinuria, an increased susceptibility to thrombotic epis... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) ES (Completed) NL (Completed) FR (Completed) GB (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-003233-34 | Sponsor Protocol Number: 11048 | Start Date*: 2012-01-19 |
Sponsor Name:University of Nottingham | ||
Full Title: The effect of intravenous iron on postoperative transfusion requirements in hip fracture patients – a pilot study | ||
Medical condition: Anaemia following hip fracture | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-001525-27 | Sponsor Protocol Number: SNOXH94C201 | Start Date*: 2012-07-19 | ||||||||||||||||
Sponsor Name:NOXXON Pharma AG | ||||||||||||||||||
Full Title: Phase IIa study to characterize the effects of the Spiegelmer® NOX-H94 on anemia of chronic disease in patients with cancer | ||||||||||||||||||
Medical condition: anemia of chronic disease in patients with cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: AT (Prematurely Ended) BG (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-003855-38 | Sponsor Protocol Number: PIERAID-2013 | Start Date*: 2014-09-26 |
Sponsor Name:Miguel Giovanni Uriol Rivera | ||
Full Title: Benefits of paricalcitol (Selective vitamin D receptor activator indicated for the prevention and treatment of secondary hyperparathyroidism) on anaemia of inflammation in dialysis patients receiv... | ||
Medical condition: Anaemia of inflammation in patients with chronic kidney disease on haemodialysis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-005317-40 | Sponsor Protocol Number: Herlev | Start Date*: 2021-05-27 |
Sponsor Name:Odense University Hospital - Department of Cardiology | ||
Full Title: Empagliflozin to elderly and obese patients with cardiovascular disease (Empire Prevent): A randomized controlled trial | ||
Medical condition: Obese patients (BMI >28 kg/m2), aged 60-84 years, with documented cardiovascular disease but no history of diabetes mellitus or heart failure with reduced ejection fraction. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-000348-22 | Sponsor Protocol Number: KER047-IR-201 | Start Date*: 2021-08-10 |
Sponsor Name:Keros Therapeutics, Inc. | ||
Full Title: A Phase 2, Open-label, Dose Escalation and Dose Expansion Study of KER-047 for the Treatment of IRIDA | ||
Medical condition: Iron-Refractory Iron-Deficiency Anemia (IRIDA) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Prematurely Ended) ES (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2020-003923-40 | Sponsor Protocol Number: APHP200019 | Start Date*: 2021-01-08 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS ( AP-HP) | |||||||||||||
Full Title: A Multicentre Concealed‐Allocation Parallel‐Group Blinded Randomized Controlled Trial to Ascertain the Effect of High‐Dose Intravenous Vitamin C Compared to Placebo on Mortality or Persistent Organ... | |||||||||||||
Medical condition: Sepsis complicated by ARDS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-002507-34 | Sponsor Protocol Number: GSN000200 | Start Date*: 2014-02-20 | |||||||||||||||||||||
Sponsor Name:Genkyotex Innovation SAS | |||||||||||||||||||||||
Full Title: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study Evaluating the Safety and Efficacy of Oral GKT137831 in Patients with Type 2 Diabetes and Albuminuria | |||||||||||||||||||||||
Medical condition: Patients with type 2 diabetes and albuminuria. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Completed) CZ (Completed) PL (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2022-000478-25 | Sponsor Protocol Number: MK-7962-008 | Start Date*: 2023-02-20 | |||||||||||
Sponsor Name:Merck Sharp & Dohme LLC | |||||||||||||
Full Title: A Phase 2 Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Sotatercept (MK-7962) in Children from 1 to Less Than 18 Years of Age With PAH on Standard... | |||||||||||||
Medical condition: Pulmonary arterial hypertension | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) NL (Trial now transitioned) PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004471-39 | Sponsor Protocol Number: IMR-SCD-301 | Start Date*: 2020-06-24 | |||||||||||
Sponsor Name:IMARA, Inc. | |||||||||||||
Full Title: A Phase 2b Study to Evaluate the Safety and Efficacy of IMR-687 in Subjects with Sickle Cell Disease | |||||||||||||
Medical condition: Sickle Cell Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) NL (Prematurely Ended) GR (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000065-16 | Sponsor Protocol Number: DS102A-07-CV1 | Start Date*: 2020-08-11 | ||||||||||||||||
Sponsor Name:Afimmune Ltd. | ||||||||||||||||||
Full Title: A Randomised, Double-Blind, Placebo-Controlled, Dose Finding Phase IIb Study to Assess the Efficacy and Safety of Orally Administered Epeleuton in Patients with Hypertriglyceridemia and Type 2 Diab... | ||||||||||||||||||
Medical condition: Hypertriglyceridemia and Type 2 Diabetes | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) LV (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
